15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
ANALYST CONSENSUS0 ratings
No Rating
Strong Buy00%
Buy00%
Hold00%
Sell00%
Strong Sell00%
Analyst rating coverage is not available for VMD yet.
12-MONTH PRICE TARGET
—
Average analyst target vs $12.12 current
Highest Target—
Average Target—
Lowest Target—
VMD EPS & revenue forecast
EPS · NEXT QUARTER
$0.13
Range $0.13 – $0.13 · 1 analysts · +44% YoY
Next period, 1 analysts expect Viemed Healthcare Inc to earn $0.13 a share (range $0.13 – $0.13), versus $0.09 a year earlier. Full-year consensus is $0.46, growing to $0.61 the year after.
REVENUE · NEXT QUARTER
$80.8M
Range $80.6M – $81.1M · 1 analysts · +12% YoY
Revenue is expected to reach $80.8M (range $80.6M – $81.1M), +12.4% year-over-year. Full-year consensus is $317.3M, rising to $360.4M next year.
VMD stock forecast FAQ
What is Viemed Healthcare Inc's projected EPS for next quarter?+
The consensus estimate is $0.13 per share (range $0.13 – $0.13) across 1 analysts. Full-year EPS is projected at $0.46, rising to $0.61 the following year.
How much revenue is Viemed Healthcare Inc expected to report next quarter?+
Consensus revenue is $80.8M (range $80.6M – $81.1M). Full-year revenue is projected at $317.3M, growing to $360.4M next year.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VMD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
